GETRALINE – Trademark Portfolio
Entity Type: 99
GETRALINE holds 5 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 42 (Computer & Scientific) — 5 filings in this category. The portfolio also extends into Class 9 (Computers & Electronics) across 6 Nice Classification classes. Currently, 3 trademarks are registered and 2 are pending. Notable registered marks include GETRALINE and IQR CONNECT.
15 rue d'Angiviller
F-78000 VERSAILLES
Showing of trademarks Trademarks
Trademark Classifications
GETRALINE's trademark portfolio spans 6 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Scientific and technological services; industrial analysis and research services
Scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments
Advertising; business management; business administration; office functions
Legal services; security services for the protection of property and individuals
Frequently Asked Questions
How many trademarks does GETRALINE have?
GETRALINE has 5 U.S. trademarks filed with the USPTO. Of these, 3 registered, 2 pending.
What trademark classes does GETRALINE file in?
GETRALINE files trademarks across 6 Nice Classification classes. The most active classes are Class 42 (Computer & Scientific), Class 9 (Computers & Electronics), Class 38 (Telecommunications), Class 35 (Advertising & Business), Class 37 (Building & Construction). Class 42 covers scientific and technological services; industrial analysis and research services.
What are GETRALINE's most well-known trademarks?
GETRALINE's registered trademark portfolio includes well-known marks such as GETRALINE and IQR CONNECT. These are among 3 currently registered trademarks in the portfolio.
What is GETRALINE's trademark registration success rate?
GETRALINE has a 100% trademark registration rate, with 3 out of 3 resolved applications resulting in successful registration. Currently, 2 applications are pending review.